Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $13.00

Stoke Therapeutics (NASDAQ:STOK) had its price objective boosted by equities research analysts at JPMorgan Chase & Co. from $6.00 to $13.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential downside of 8.26% from the company’s previous close.

Several other brokerages have also recently issued reports on STOK. Needham & Company LLC reissued a “buy” rating and set a $14.00 price objective on shares of Stoke Therapeutics in a research note on Friday, February 16th. Canaccord Genuity Group lifted their price objective on Stoke Therapeutics from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $19.63.

Stoke Therapeutics Price Performance

STOK opened at $14.17 on Tuesday. The stock has a market capitalization of $632.69 million, a price-to-earnings ratio of -5.98 and a beta of 0.68. Stoke Therapeutics has a 12 month low of $3.35 and a 12 month high of $16.40. The business has a 50-day moving average of $5.88 and a two-hundred day moving average of $4.95.

Insider Buying and Selling

In other Stoke Therapeutics news, CFO Stephen J. Tulipano sold 4,116 shares of the stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $25,107.60. Following the completion of the sale, the chief financial officer now owns 20,746 shares of the company’s stock, valued at $126,550.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Barry Ticho sold 10,000 shares of Stoke Therapeutics stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $4.80, for a total transaction of $48,000.00. Following the sale, the insider now directly owns 6,981 shares of the company’s stock, valued at $33,508.80. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Stephen J. Tulipano sold 4,116 shares of the business’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $25,107.60. Following the completion of the transaction, the chief financial officer now owns 20,746 shares in the company, valued at approximately $126,550.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 37,615 shares of company stock valued at $212,852. Corporate insiders own 12.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds have recently bought and sold shares of STOK. Bank of New York Mellon Corp raised its position in shares of Stoke Therapeutics by 1.4% in the 1st quarter. Bank of New York Mellon Corp now owns 62,698 shares of the company’s stock valued at $1,320,000 after purchasing an additional 837 shares in the last quarter. American International Group Inc. increased its stake in shares of Stoke Therapeutics by 10.9% in the second quarter. American International Group Inc. now owns 10,506 shares of the company’s stock worth $139,000 after buying an additional 1,029 shares during the last quarter. Great West Life Assurance Co. Can raised its holdings in Stoke Therapeutics by 46.7% in the first quarter. Great West Life Assurance Co. Can now owns 3,387 shares of the company’s stock valued at $28,000 after acquiring an additional 1,078 shares in the last quarter. Ensign Peak Advisors Inc bought a new position in Stoke Therapeutics during the 1st quarter valued at $25,000. Finally, Point72 Hong Kong Ltd acquired a new position in Stoke Therapeutics during the 1st quarter worth $27,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.